Table 1Conversion of Sulfonylurea into Glimepiride-Equivalent Dose [1011]
Variable |
Equivalent dose, mg/day |
Glimepiride |
1 |
Gliclazide |
80 |
Gliclazide-modified release |
30 |
Glibenclamide |
5 |
Table 2Changes in Glycemia according to SU and Concurrent Antidiabetic Medications
Variable |
(A) Baseline |
(B) After SU-free period (4.8±1.5 mo) |
(C) After SU re-use (2.4±0.8 mo) |
Post hoc analysis by Tukey's multiple comparison test, if repeated measures ANOVA P<0.05 |
P for A vs. B |
P for B vs. C |
P for A vs. C |
FPG, mg/dL |
129.2±20.2 |
206.0±47.5 |
142.4±23.6 |
<0.0001 |
<0.0001 |
NS |
Glycated hemoglobin, % |
6.7±0.4 |
8.8±0.8 |
7.4±0.7 |
<0.0001 |
<0.0001 |
<0.001 |
SU as glimepiride-equivalent, mg/daya
|
1.0±0.6 |
0 |
1.3±0.8 |
<0.001 |
<0.001 |
NS |
Concurrent antidiabetic agents, mg/day |
Metformin |
1,390±590 (n=17) |
1,400±510 (n=19) |
1,290±530 (n=18) |
NA |
NA |
NA |
Pioglitazone |
15±0 (n=4) |
14±3 (n=7) |
15±0 (n=4) |
NA |
NA |
NA |
DPP-4 inhibitors |
100±0 (n=5)b
|
94±17 (n=9)b,c
|
90±22 (n=5)b
|
<0.05 |
<0.05 |
NS |
Table 3Characteristics of the SU-Dependent Subjects (n=19)
Variable |
Value |
Age, yr |
67±11 |
Male sex, % |
57.9 |
Weight, kg |
65.3±10.6 |
Body mass index, kg/m2
|
25.1±3.1 |
Duration of diabetes, yr |
18±10 |
DM in 1st degree family, % |
73.7 |
Systolic blood pressure, mm Hg |
134.9±14.6 |
Diastolic blood pressure, mm Hg |
76.2±12.1 |
Glycated hemoglobin, % |
6.7±0.4 |
Fasting serum glucose, mg/dL |
129.2±20.2 |
C-peptide (n=10), ng/mL |
3.9±2.6 |
Total cholesterol, mg/dL |
150.8±35.3 |
Triglyceride, mg/dL |
113.5±51.8 |
Urine albumin/creatinine ratio, mg/g |
21.2±16.6 |
eGFR, mL/min/1.73 m2
|
75.8±18.0 |
SU duration, yr |
12±9 |
SU, number (%)/mean dose, mg/day |
|
Glimepiride |
8 (42.1)/1.1±0.8 |
Gliclazide |
4 (21.1)/70.0±20.0 |
Gliclazide modified release |
2 (10.5)/30±0 |
Glibenclamide |
5 (26.3)/2.5±1.5 |